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ORIGINAL RESEARCH
INTERVENTIONAL
Outcome Study of the Pipeline Embolization Device with
Shield Technology in Unruptured Aneurysms (PEDSU)
D. Atasoy, N. Kandasamy, J. Hart, J. Lynch, S.-H. Yang, D. Walsh, C. Tolias, and T.C. Booth
ABSTRACT
BACKGROUND AND PURPOSE: The recently introduced Pipeline Flex Embolization Device with Shield Technology (Pipeline Shield)
is the third generation of Pipeline flow-diverter devices. It has a new stent-surface modification, which reduces thrombogenicity.
We aimed to evaluate clinical and radiographic (safety and efficacy) outcomes of the Pipeline Shield.
MATERIALS ANDMETHODS: The 30-day and 1-year mortality and morbidity rates and the 6- and 18-month radiographic aneurysm occlu-
sion outcomes for procedures performed between March 2016 and January 2018 were analyzed. 3D-TOF-MRA was used for follow-up.
RESULTS: Forty-four attempted Pipeline Shield procedures were performed for 41 patients with 44 target aneurysms (total of 52
aneurysms treated). A total of 88.5% of devices were inserted in the anterior circulation, and 11.5%, in the posterior circulation;
49/52 (94.2%) aneurysms were saccular; and 1/52 (1.9%) was fusiform. One (1.9%) aneurysm was an iatrogenic pseudoaneurysm, and 1
(1.9%) was a dissecting aneurysm. Seventy-one percent (35/49) of the saccular aneurysms were wide-neck (neck, .4mm), 34.6%
(18/52) were large ($10mm), and 3.8% (2/52) were giant ($25mm). The mean aneurysm sac maximal diameter was 9.0mm, and the
mean neck width was 5.0mm. The cumulative mortality and morbidity rates were 2.3% and 6.8% at 1 year, respectively. The
adequate occlusion rate was 78.8% at 6months and 90.3% at 18months.
CONCLUSIONS: In this pragmatic and non-industry-sponsored study, the occlusion rates and safety outcomes were similar to
those seen in previously published studies with flow-diverter devices and earlier generation Pipeline Embolization Devices.
F low-diverter devices have been used to treat cerebral aneur-ysms for nearly 10 years. These devices occlude aneurysms
through endoluminal reconstruction and remodeling of the par-
ent artery.1 The Pipeline Embolization Device (PED; Covidien,
Irvine, California) is 1 of 2 FDA-approved flow-diverter devices.2
The first generation of PEDs has been used effectively and safely
for many years.3-5 The second generation, the Pipeline Flex
Embolization Device (Covidien), had a redesigned delivery
system enabling better repositioning and redeployment of the
stent.6,7 Nonetheless, thromboembolic complications remain
an important cause of morbidity in both generations of PEDs.3
Thus, a third generation, the Pipeline Flex Embolization
Device with Shield Technology (Pipeline Shield; Covidien) was
recently produced (Fig 1). The second-generation delivery sys-
tem remained the same; however, there is a new phosphoryl-
choline stent-surface modification aimed at minimizing
thrombogenicity.8 Because there is no difference in cost
between the Pipeline Shield and earlier PED devices, the
Pipeline Shield has been adopted as the default PED, though
there are limited clinical data to support its use. In this study,
we demonstrate clinical and radiographic (safety and efficacy)
outcomes of the third-generation PED.
MATERIALS AND METHODS
Patient Selection
All patients who underwent Pipeline Shield placement at a single
center between March 2016 and January 2018 were included in
this pragmatic and retrospective cohort study. All cases were
selected following a consensus decision at a neurovascular
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multidisciplinary team meeting, which included interventional
neuroradiologists and neurovascular surgeons. A high neck-to-
sac ratio, a high probability of aneurysm recurrence, and
increased neurosurgical technical difficulty were the factors lead-
ing to Pipeline Shield treatment in preference to coiling, stent-
assisted coiling, or neurosurgery.9
Procedural Details
Patients started dual-antiplatelet therapy (aspirin and clopidog-
rel) 7 days before their procedure and continued clopidogrel once
daily for 6–9months and continued aspirin for life (all doses,
75mg daily). Platelet-resistance testing was not performed at our
center due to our interpretation of the literature indicating a lack
of evidence to show a proven clinical benefit.10-13
Pipeline Shield placement procedures were performed with
the patient under general anesthesia using biplane angiography
(Allura Xper FD, Philips Healthcare, Amsterdam, Netherlands).
All procedures were performed with a femoral arterial approach
with 6F or 8F guiding-catheter systems (0.088-inch NeuronMax
or 6F Benchmark, both Penumbra, Alameda, California; Shuttle
guide sheath, Cook, Bloomington, Indiana), which were posi-
tioned in the cervical segment of the ICA ipsilateral to the target
aneurysm or a distal V2 segment. A triaxial system, incorporating
a 0.058- or 0.072-inch intracranial support catheter (Navien,
Covidien, Irvine, California) was used in both the anterior and
posterior circulations. The Pipeline Shield device was deployed
using a 0.027-inch microcatheter (Phenom 27 or Marksman;
both Covidien). Embolization catheters (Echelon, Covidien; or
Excelsior SL10, Stryker, Kalamazoo, Michigan) were used for
adjunctive coil delivery in selected
cases. Patients typically were dis-
charged home the morning after the
procedure.
Data Collection
Electronic patient records (Allscripts
Sunrise, Chicago, Illinois); preproce-
dural, procedural, and postproce-
dural images on the PACS; and
written procedural records for patients
treated with the Pipeline Shield were
reviewed. Data on aneurysm size and
location were acquired from DSA
images (Allura Xper FD, Philips
Healthcare, Amsterdam, Netherlands).
As in a previous PED study,9 the first
posttreatment follow-up was performed
typically at 6months postprocedure
using 3D-TOF-MRA (Signa 1.5 T
HDX; GE Healthcare; or AERA 1.5T,
Siemens, Erlangen, Germany) with re-
spective TR = 23 or 25ms, TE = 2.5 or
7ms, flip angle = 20° or 25° (with
ramped pulse), matrix = 320  224 or
241  256; FOV = 19  19 or 18 
18 cm, section thickness = 1.4mm
(reconstructed to 0.7 or 0.5mm, respectively). If there were new
clinical features during follow-up, an earlier MR imaging (with
MRA) or CT (with CTA) was performed on a case-by-case basis.
All images were reviewed in the neurovascular multidisciplinary
team meeting, and further follow-up 3D-TOF-MRA was typically
scheduled for 18months postprocedure. All data were reviewed
and analyzed by an independent core laboratory (D.A.).
Aneurysm occlusion status was classified using the Raymond-
Roy Outcome Classification (Raymond Scale): class 1, complete
occlusion; class 2, residual neck; and class 3, residual aneurysm.
To compare our results with those of the largest clinical trial of
PEDs to date (the International Retrospective Study of the
Pipeline Embolization Device (InttrePED)3), we used the identi-
cal adverse event classification. A neurologic adverse event
included rupture of the target aneurysm causing subarachnoid
hemorrhage or carotid cavernous fistula, intraparenchymal hem-
orrhage, ischemic stroke, parent artery stenosis, and cranial neu-
ropathy. A persistent clinical deficit at 7 days following the event
was defined as a “major” adverse event. Other events that
resolved within 7 days with no clinical sequelae were defined as
“minor” adverse events.
Statistical Analysis
Descriptive and comparative statistical analyses were per-
formed using SPSS (Version 23.0; IBM, Armonk, New York).
Student t tests or Mann-Whitney tests were used. All adverse
events were reviewed on an intention-to-treat basis. Aneurysm
characteristics and occlusion rates were performed on a per-
aneurysm basis because some patients had .1 aneurysm
treated with$1 PED.
FIG 1. Illustration of Pipeline Shield mechanism and structure. A, Before Pipeline Shield deploy-
ment, the blood flow is through both the parent artery and the aneurysm. B, However, after de-
vice deployment, the blood flow in the aneurysm is reduced or disrupted. C, A schematic
showing the magnified appearance of the braided wires of the Pipeline Shield. D, A 3D illustration
of the phosphorylcholine molecule, which is covalently bound onto the bare metal wires in a
polymer form, resulting in physiologic imitation of the cell membrane.
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Ethical Statement
Written informed consent was obtained from all patients. We
received written confirmation from the Research and Innovation
Department at King’s College Hospital that the Health Research
Authority of the UK does not require review by a Research Ethics
Committee, given the nature of the retrospective study using de-
identified data. The study was performed in accordance with the
ethical standards laid down in the 1964 Declaration of Helsinki
and its later amendments.
RESULTS
Patient and Aneurysm Characteristics
There were 41 patients between March 2016 and January 2018
whom we intended to treat with the Pipeline Shield device. The
mean age was 56 years (range, 17–82 years), and 68.3% (28/41) of
patients were women.
There were no acutely ruptured aneurysms. There had been
prior treatment of intracranial aneurysm with coils in 32.6% (17/
52) of aneurysms. The mean aneurysm neck width was 5.0mm,
the mean sac maximal diameter was 9.0mm, 34.6% (18/52) were
large ($10mm), and 3.8% (2/52) were giant ($25mm) (Table
1). Forty-nine (94.2%) aneurysms were saccular, and 1 (1.9%)
was fusiform. One (1.9%) aneurysm was an iatrogenic pseudoan-
eurysm, and 1 (1.9%), a dissecting aneurysm. Seventy-one per-
cent (35/49) of the saccular aneurysms were wide-neck (neck,
.4mm). Most aneurysms were located in the anterior circula-
tion, 46/52 (88.5%); 6/52 (11.5%) were located in the posterior
circulation.
A total of 44 attempted Pipeline Shield procedures were per-
formed for the 41 patients with 44 target aneurysms (total, 52
aneurysms treated; there were 8 cases in which the device covered
additional nontarget aneurysms). Three patients who had been
treated for ICA aneurysms had a second Pipeline Shield proce-
dure for aneurysms located in the contralateral ICA within
1month. Two patients each received 2 Pipeline Shields for 1 tar-
get aneurysm in a single procedure. Device-deployment success
(release of the Pipeline Shield at the target site) was achieved
in 45 of 46 (97%) of the attempted Pipeline Shield deployments.
It was not possible to deploy a Pipeline Shield in 1 patient who
had a wide-neck saccular M1 segment aneurysm. Deployment
was unsuccessful because the Pipeline Shield would not travel
through the Marksman catheter, which was within a 0.058
Navien intracranial support catheter placed inside a tortuous cer-
vical ICA. The aneurysm was subsequently treated with a LEO
Baby stent (Balt Extrusion, Montmorency, France) and coils.
Stable complete occlusion (Raymond scale 1) at 18-month fol-
low-up was seen. In total, 45 devices were deployed in the 44 pro-
cedures. The mean number of deployed devices per aneurysm
was 0.86 (45/52) or, if nontarget aneurysms were ignored, 1.02
(44/45). No thromboembolic or hemorrhagic events occurred
during the procedures.
Periprocedural Clinical Outcomes
The periprocedural mortality rate was 1/44 (2.3%) Pipeline Shield
procedures (Table 2). This patient had a recurrent giant basilar
termination aneurysm after previous coiling treatment. This an-
eurysm measured 27mm in maximum dimension with a 10-mm
recurrent sac diameter. He had an acute subdural hematoma
15 days after the successful Pipeline Shield deployment with ad-
junctive coiling and died 16days after the procedure. There were
2 periprocedural major events including this death, 2/44 (4.6%).
The second major event gave a periprocedural neurologic mor-
bidity rate of 2.3% (1/44). This patient was treated with 2 Pipeline
Shield devices for a giant (28mm) right cavernous segment ICA
aneurysm. On day 7 postprocedure, the patient was re-admitted
with an ipsilateral third nerve palsy. A head CT revealed the
expected appearances of a thrombosed aneurysm. The third cra-
nial nerve palsy was attributed to the thrombosed aneurysm. At
the time of presentation, the patient also experienced a headache
(Universal Pain Assessment Tool for headache, 5/10). CT of the
head also showed a new small remote right temporal intraparen-
chymal hematoma. The patient was managed symptomatically
for headache, and in view of the hemorrhage, clopidogrel was
stopped temporarily with the patient continuing on aspirin.
Following appropriate evolution of the right temporal hemor-
rhage on follow-up CT, clopidogrel therapy was restarted and the
patient was discharged with no headache. There were 2 peripro-
cedural minor events, including the headache described here,
Table 1: Aneurysm characteristics
Characteristic
No. (%) or
Mean (Range)
Aneurysm location
Anterior circulationa 46 (88.5)
ICA cavernous segment 2 (3.8)
ICA paraophthalmic segment 29 (55.7)
ICA posterior communicating segment 12 (23.1)
ICA terminal segment 2 (3.8)
M1 segment of MCA 1 (1.9)
Posterior circulation 6 (11.5)
Basilar artery 3 (5.8)
Vertebral artery 2 (3.8)
Posterior cerebral artery 1 (1.9)
Neck width (mmb) 5.0 (1.0–21.0)
Maximum aneurysm sac diameter (mmb) 9.0 (1.0–28.0)
,10 32 (60.8)
10–25 18 (34.6)
$25 2 (3.8)
PED number (per aneurysm) 0.86 (45/52)
Adjunctive coils placed 15 (28.8)
a ICA according to the New York University classification.14
bMillimeter to the nearest 0.5.
Table 2: Clinical outcomes
Outcome
Procedure
No. (%)
Periprocedural outcomes (within 30 days)
Major adverse eventsa
Death from subdural hemorrhage 1 (2.3)
Cranial nerve palsyb 1 (2.3)
Minor adverse events
Stroke/TIA 1 (2.3)
Headacheb 1 (2.3)
Postprocedure outcomes (30 days to 1 yr)
Major adverse eventsa
Pulsatile tinnitus (carotid cavernous fistula) 1 (2.3)
Mass effect causing reduced visual acuity 1 (2.3)
a An ongoing clinical event at 7 days following the event.
b Same patient.
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with a total of 2/44 (4.6%). The second minor event yielded a
2.3% (1/44) stroke/TIA rate. This patient had a TIA with a tem-
porary left-sided facial droop and slurred speech 6 days after
right ICA PED deployment. CT, MR imaging, and MRA showed
no intracranial hemorrhage or recent infarct. The patient was
also known to have atrial fibrillation and was referred to the
TIA clinic.
MRA Outcomes
Follow-up MRA was performed in 38/40 patients who had
undergone technically successful procedures. One patient died
16 days postprocedure, and the other patient refused imaging fol-
low-up (the patient is clinically healthy). The mean follow-up
time until the first MRA was 5.8months (range, 1–7 months).
Within 6 Months. We classified 3 aneurysms as nonoccluded1
because the first follow-up MRA was performed after 6months
(despite the follow-up .6-month MRA showing occlusion).
Similarly, we classified the aneurysm in the patient who refused
follow-up imaging as nonoccluded. Therefore, within 6months,
78.8% (41/52) of aneurysms achieved adequate occlusion
(Raymond scale 1 or 2) or remodeling (1 dysplastic fusiform
and 1 dissecting aneurysm) (Table 3). The complete occlusion
rate (Raymond scale 1) was 69.2% (36/52). A residual aneurysm
sac remnant (Raymond scale 3) was seen in 21.1% (11/52) of
aneurysms at 6months.
Between 6 and 18 Months. We classified the aneurysm in the
patient who refused follow-up imaging as nonoccluded. The
mean follow-up time until the second MRA was 17.2months
(range, 7–20 months). Six additional aneurysms were completely
occluded (Raymond scale 1). The total adequate occlusion rate
(Raymond scale 1 and 2) in this study was 90.3% (47/52), and the
complete occlusion rate (Raymond scale 1) was 82.7% (43/52) at
18months.
The maximum sac diameters of aneurysms with residual sac
filling (Raymond scale 3) and aneurysms that showed complete
occlusion (Raymond scale 1) were not significantly different (P =
.28; mean, 11.5mm [range, 4.0–22.0 mm] versus mean, 8.5mm
[range, 1.0–28.0 mm)]. The neck
width of aneurysms with residual sac
filling (Raymond scale 3) was not
significantly different from that of
those with complete occlusion (Raymond
scale 1) (P=.10; mean, 8.0mm [range,
3.0–21.0 mm] versus mean, 4.5mm
[range, 1.0–16.0mm]).
No in-stent stenosis was identified
at either follow-up time point.
In summary, the adequate occlu-
sion rate and the complete occlusion
rate were 78.8% (41/52) and 69.2%
(36/52), respectively, at 6months. At
18 months, the adequate occlusion
rate was 90.3% (47/52) and the com-
plete occlusion rate was 82.7% (43/
52).
Postprocedural Clinical Outcomes 30 Days to 1 Year
One patient experienced blurry vision 3months following the
procedure, and ophthalmologic examination showed papille-
dema (Table 2). MRA at 5 months postprocedure showed
that there was residual neck filling (Raymond Scale 2; 8 -mm
neck remnant) in a paraophthalmic segment aneurysm
(Fig 2). The stent was no longer covering the entire aneurysm
neck, and the aneurysm cross-sectional diameter had
increased during the 5-month interval from 17 to 32mm. The
aneurysm was re-treated with a larger diameter flow-diverter
device, the Flow-Redirection Endoluminal Device (FRED;
MicroVention, Tustin, California), which was deployed
across the uncovered neck. The rationale was that this larger
stent would give superior apposition to the parent vessel
lumen distal to this segment. MRA performed 1, 2, and
6months after the second procedure showed stability of the
aneurysm cross-sectional diameter with a reduction in the
neck remnant size (Raymond Scale 2; 4 mm).
There was 1 further major adverse event. This patient had a
recurrent left cavernous segment ICA 9.5-mm wide-neck an-
eurysm after coiling. During the procedure, there was a tran-
sient iatrogenic carotid cavernous fistula, which had resolved
by the end of the procedure when the Pipeline Shield was satis-
factorily deployed across the neck of the aneurysm. However,
the patient presented with sudden-onset pulsatile tinnitus
1month later, and DSA showed that there was recurrent ca-
rotid cavernous fistulation (note that because our methodol-
ogy used the IntrePED study adverse event classification as
described above, this was classified as a postprocedural event).
This fistula was treated with coil embolization. There were no
further clinical sequelae.
Cumulative adverse events of any sort occurred after treatment
of 4 anterior circulation aneurysms from a total of 38 (10.5%) tar-
get aneurysms. There was 1 adverse event (periprocedural subdural
hematoma) that occurred after treatment of a posterior circulation
aneurysm from a total of 6 (16.7%) target aneurysms.
No aneurysms ruptured periprocedurally or at 1-year fol-
low-up.
Table 3: Image outcomea
Outcome
Aneurysm
No. (%) or
Mean (Range)
Adequate occlusion/remodeling at 6months (Raymond scale 1 and 2) 41 (78.8)
No residual neck or sac (Raymond scale 1) 36 (69.2)
Residual neck (Raymond scale 2) 5 (9.6)
Residual sac (Raymond scale 3) 11 (21.1)
Adequate occlusion/remodeling at 18months (Raymond scale 1 and 2) 47 (90.3)
No residual neck or sac (Raymond scale 1) 43 (82.7)
Residual neck (Raymond scale 2) 4 (7.7)
Residual sac (Raymond scale 3) 5 (9.6)
Mean size of aneurysms (mm)
Residual sac (Raymond scale 3) 11.5 (4.0–22.0)
No residual neck or sac (Raymond scale 1) 8.5 (1.0–28.0)
Mean size of neck (mm)
Residual sac (Raymond scale 3) 8.0 (3.0–21.0)
No residual neck or sac (Raymond scale 1) 4.5 (1.0–16.0)
aMillimeter to the nearest 0.5.
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DISCUSSION
This pragmatic and non-industry-sponsored outcome study adds
to the limited safety and efficacy outcome evidence of the third-
generation Pipeline Shield. In contrast to earlier generation
PEDs, which have been studied extensively,3,7,15-19 there is only 1
recent industry-sponsored prospective study (Pipeline Flex
Embolization Device with Shield Technology (PFLEX))16,20 and
several case reports21,22 examining the Pipeline Shield when used
to treat aneurysms that have not acutely ruptured. We analyzed
the 30-day and 1-year mortality and morbidity rates, and the 6-
and 18-month radiographic aneurysm occlusion outcomes.
Clinical Outcomes
Our overall mortality rate was 2.3%, which was lower than the
3.8% seen in the IntrePED study (the largest clinical trial for pre-
vious generation PEDs)3 and higher than the PFLEX study, which
was 0%.20 The 1 death in our study was caused by a subdural he-
matoma 15 days after treatment.
The overall morbidity rate of 6.8% in our study (1 peripro-
cedural and 2 postprocedural major adverse events in 44 proce-
dures) is similar to that in a very similar study using previous-
generation devices (10.0%)9 as well as the IntrePED study
(7.4%).3 Two of the major adverse events occurred in giant
aneurysms, and 1, in a large aneurysm, again highlighting the
higher complication risk associated with PED (or any) treat-
ment of large or giant aneurysms ($ 10mm). Because the
PFLEX study used a different outcome classification from the
IntrePED study classification, which was used in the current
study, a direct comparison with the PFLEX outcomes was
limited. For indirect comparison, the PFLEX study showed
0% major strokes (defined as the NIHSS score increasing by
4 points) or neurologic deaths at 1 year postprocedure.
However, there were 6% (3/50) procedure-related adverse
events (headache, diplopia, and retroperitoneal hematoma)
categorized as serious in the PFLEX study. Events including a
carotid dissection and a cerebral infarction (the NIHSS score
changed by #3 points) also occurred but were considered
nonserious events.
In vitro, ex vivo, and in vivo studies have shown reduced
thrombogenicity of the Pipeline Shield compared with the PED
without phosphorylcholine surface modification.8,23,24 There are
no clinical data to prove that surface modification results in
improved clinical outcomes, but the following observations sug-
gest that surface modification does not worsen clinical outcomes.
No thromboembolic events occurred during the procedure; 1
patient (2.3%), who also had atrial fibrillation, had a periproce-
dural thromboembolic event; and no thromboembolic events
occurred during postprocedural follow-up. In the PFLEX study,
FIG 2. Pipeline Shield case. A, CTA shows a right ICA paraophthalmic segment aneurysm measuring 17mm in maximal sac diameter before treat-
ment. B, Digital subtraction angiography oblique view shows the aneurysm after treatment with a 5  14mm Pipeline Shield and 7 adjunctive
coils. The landing zone (arrow) was selected as shown because the ICA paraophthalmic segment lumen was 5.00mm in diameter, the ICA poste-
rior communicating artery segment lumen was 4.75mm in diameter (wider at the infundibulum), and the ICA terminal segment was 5.5mm in di-
ameter. The nominal maximum diameter of the largest Pipeline Shield is 5.0mm with a maximum unconstrained diameter of 5.25mm. C,
Different oblique view without subtraction after treatment. The Pipeline Shield (arrows) has a flared appearance as it bulges into the infundibu-
lum of the ICA posterior communicating artery segment. D, MR imaging at 5 months postprocedure shows that the aneurysm cross-sectional di-
ameter had increased during the 5-month interval from 17 to 32mm. The stent was no longer covering the entire aneurysm neck in the ICA
paraophthalmic segment. E and F, The aneurysm was re-treated by telescoping a larger-diameter flow-diverter device (FRED, MicroVention;
arrows show proximal and distal markers), measuring 5.5 14mm, through the Pipeline Shield, across the small segment of uncovered neck, and
landing the stent in the ICA terminal segment. Anesthetic equipment is superimposed over the image.
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there were no procedural or periprocedural thromboembolic
events; but 1 patient experienced a thromboembolic event at
1 year (2%). In comparison, the previous-generation PEDs led to
a periprocedural thromboembolic event rate of 6.5% and 3.3% in
the ipeline Embolization Device for the intracranial treatment of
aneurysms trial (PITA)1 and IntrePED3 studies respectively; and
in 2 large meta-analyses of flow-diverter device treatment, the
rate was 3.6% and 5%.25,26 At a median follow-up of 19months,
there was a cumulative 4.7% thromboembolic event rate in the
IntrePED study. Although the numbers are too small for a com-
parative multivariate analysis, a very similar pragmatic study at
our center using previous-generation PEDs yielded a cumulative
10.0% thromboembolic event rate.9 Taken together, the data
from these studies and the current study suggest that there is no
reason to refute the in vitro, ex vivo, and in vivo (animal and clin-
ical) evidence of the low thrombogenicity of the Pipeline Shield.
Occlusion Rates
Our complete occlusion (Raymond scale 1) rate was 69.2% at
6months and 82.7% at 18months. Our results are not dissimi-
lar to those of flow-diverter device studies in general (ranging
between 55% and 95% during various follow-up intervals)27,28
or the studies described below using the PED only. Our study
of the first 2 generations of PEDs, also using 3D-TOF-MRA
follow-up, yielded similar complete occlusion rates at 6 and
18months (65.6% and 78.1%, respectively).9 At the 1-year fol-
low up of the PFLEX study,20 the complete aneurysm occlu-
sion rate was 81.8%.
We note that the pipeline for uncoilable or failed aneurysms
study (PUFS)5 study had a complete occlusion rate of 86.8% at 1-
year follow up and the PITA1 had 93.3% at 6-month follow up,
which were higher than our occlusion rates. Although statistical
comparison cannot be made directly among the different studies,
we make the following tentative observations: First, the mean
aneurysmal sac size in these studies was larger than that in our
study (18.0 and 11.5mm compared with 9.0mm in our study), so
the putative occlusion rate differences are unlikely to be caused
by a difference in aneurysm size (indeed, a meta-analysis with
flow-diverter devices showed no relationship between the occlu-
sion rates and sac diameter of aneurysms5). Second, the putative
occlusion rate differences are unlikely to be caused by a difference
in adjunctive coiling because the PITA study adjunctive coil rate
was higher (51.6%), while the PUFS rate was lower (0.9%) com-
pared with our rate (28.8%). A lack of relationship between occlu-
sion rates and adjunctive coil rates might be expected because
there is little evidence that adjunctive coiling when using flow-di-
verter devices is beneficial.29 Anecdotally, there is more motiva-
tion for adjunctive coiling to prevent rupture of large aneurysms
during thrombosis rather than to influence occlusion rates.
Third, additional overlapping PEDs are anecdotally thought to
influence occlusion rates by increasing mesh density. It is plausi-
ble that the putative occlusion rate differences are caused by a dif-
ference in mesh density because the mean number of Pipeline
Shields used per aneurysm was 0.9 (or if nontarget aneurysms are
ignored, 1.0), whereas in PITA and PUFS, the rates were 1.5 and
3, respectively. We also note that the PFLEX study20 had an
occlusion rate similar to that in our study using a similar Pipeline
Shield rate of 1.1.
Aneurysm sac diameter is considered an important factor
influencing the occlusion rate in endovascular treatment, espe-
cially in aneurysm coiling. However, as mentioned above, a meta-
analysis with flow-diverter devices showed no relationship
between the occlusion rates and sac diameter of aneurysms.5 Our
results also did not show that the sac diameter of the Pipeline
Shield influences occlusion rates.
In contrast to the first 2 generations of PEDs studied previ-
ously,9 no significant difference in neck width was seen when
occluded and nonoccluded subgroups were compared following
Pipeline Shield treatment.
Strengths and Limitations
Studies such as PFLEX,20 PITA,1 and PUFS5 used DSA as the
follow-up technique for PED-treated aneurysms. There has
been widespread adoption of flow-diverter devices with a
range of follow-up methods and time points, and a recent
meta-analysis that compared MRA and DSA concluded that
both 3D-TOF-MRA and contrast-enhanced MRA can be used
reliably to follow up flow-diverter devices.30 The sensitivity
and specificity of TOF-MRA were 86% and 95%, respectively.
Contrast-enhanced MRA had a sensitivity and specificity of
90% and 92%. MRA has been chosen as a suitable follow-up
imaging technique in pragmatic flow-diverter device studies
including the flow diversion in the treatment of aneurysms
(FIAT) randomized controlled trial, which analyzed the safety
and efficacy of PEDs.31 As in a study of previous-generation
PEDs,9 we used 3D-TOF-MRA.
Despite the data from the meta-analysis, there may be con-
cerns that the PED can result in a marked local signal void due to
a larger bimetallic surface area coverage and radiofrequency
shielding,32,33 which may cause false-positive detection of in-stent
stenosis.34,35 However, the impact of this potential overestimation
of in-stent stenosis was negligible in our study because no in-
stent stenosis was seen on the 3D-TOF-MRA follow-up.
A further concern using 3D-TOF-MRA as a follow-up tech-
nique may relate to false-positive detection of intra-aneurysmal
residual flow, which has been recognized with TOF-MRA due
to T1-weighted hyperintensity of the thrombus.36 False-positive
detection of intra-aneurysmal residual flow in our study is likely
to be very low because other sequences (T2-weighted) and scan
planes (multiplanar reformat) were routinely reviewed. In our
institution, we have yet to discover a false-positive after a subse-
quent DSA, nor was a false-positive seen in a previous PED
study using 3D-TOF-MRA when analysis of multiple MR imag-
ing planes and sequences was also performed at follow-up.9
Furthermore, cross-sectional MR imaging confirmed complete
occlusion because a decrease in the size of the aneurysm sac on
cross-sectional imaging appears to be the single most consistent
sign of durable aneurysm occlusion (likely implying full endo-
thelialization of the device construct and secondary exclusion of
the aneurysm from the parent circulation).37,38 In contrast,
intra-aneurysmal thrombosis in a nonoccluded growing aneu-
rysm can occasionally appear on DSA as an apparently occluded
aneurysm (false-negative).
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Although contrast-enhanced MRA may theoretically over-
come some of these potential concerns, the data from the meta-
analysis (particularly at 1.5T) do not support a change of practice
at our institution from TOF to contrast-enhanced MRA, to obvi-
ate the potential drawbacks of TOF.36,39
Nonetheless, a limitation of this study is that DSA was not
performed for follow-up, which would have allowed direct com-
parison of efficacy outcomes with many previous studies and pro-
vided complementary information.
Another limitation of this study is that it was performed
in a single center and is retrospective; however, the results of
this pragmatic study are likely to be generalizable to similar
centers.9 This would be other centers with a similar operator
number (3 performing PEDs), operator experience (10, 9, and 4
years of interventional neuroradiology experience at the point
of first deployment of the Shield), neurovascular multidiscipli-
nary team composition (2 neurosurgeons, 4 interventional neu-
roradiologists, 1 stroke neurologist), and a population at risk
(3.5 million in a unit treating 160–200 aneurysms per year).
A further limitation of the study is the small absolute number
of cases. However, small numbers can be expected in a single-
center study (we note that the National Institute of Clinical
Excellence in the UK estimates that 60 PEDs are used in the
entire UK per year40), and even the seminal PITA study consisted
of only 31 aneurysms.1 Furthermore, because PFLEX included 50
patients with 50 unruptured target aneurysms, the current study,
which includes 41 patients with 44 unruptured target aneurysms,
almost doubles the total number of Pipeline Shield cases studied
(94 unruptured aneurysms).
The overall incidence of DWI positive foci presumably rep-
resenting thromboembolic events following endovascular treat-
ment of intracranial aneurysms is approximately 50%, with no
significant difference between coiling and flow diversion.13
According to some studies from the coiling and flow-diversion
literature, there is no association between the presence of DWI
lesions and neuropsychological examination performance.41,42
Nonetheless, future studies may wish to routinely perform post-
procedural DWI to investigate the rate of these foci after
Pipeline Shield deployment.
CONCLUSIONS
Our retrospective study Pipeline Embolization Device with Shield
Technology in Unruptured Aneurysms (PEDSU) is a pragmatic
and non-industry-sponsored study into clinical and radiographic
(safety and efficacy) outcomes of the third-generation Pipeline
Shield device. The study adds to the limited outcome evidence
regarding the third-generation Pipeline Shield used to treat
aneurysms that have not acutely ruptured. Our results demon-
strated that occlusion rates and safety outcomes are similar com-
pared with those in previously published studies using other
flow-diverter devices or the first 2 generations of PEDs. Follow-
up with 3D-TOF-MRA showed similar PED occlusion results
compared with those acquired with MRA or DSA from other
studies.
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